Recent News for BHVN - Biohaven Pharmaceutical Holding Company Ltd.

Date Title
Jul 13 Did Hedge Funds Make The Right Call On Biohaven Pharmaceutical Holding Company Ltd. (BHVN) ?
Jul 9 The Daily Biotech Pulse: FDA Nod For Osmotica, OptiNose Strikes Co-promotion Deal, Orphan Drug Designation For AnaptysBio
Jul 8 Kleo Pharmaceuticals Announces $5 Million Grant to Advance Development of COVID-19 Hyperimmune Globulin Mimic (HGM) as a Therapeutic for Infected Patients
Jun 24 Biohaven's troriluzole flunks obsessive-compulsive disorder study
Jun 24 Biohaven Announces Obsessive-Compulsive Disorder (OCD) Proof Of Concept Phase 2/3 Study Results And Program Update
Jun 19 The Daily Biotech Pulse: Tiziana Snags A Patent Win, Decision Day For Nabriva And Evoke, IPOs
Jun 18 The Daily Biotech Pulse: Eloxx Resumes Cystic Fibrosis Study, Rexahn's Reverse Merger, Ultragenyx, Epizyme Await FDA Decisions
Jun 17 The Daily Biotech Pulse: Patent Win For Amarin, FDA Nod For Novartis & Merck, Chembio's Coronavirus EUA Revoked
Jun 16 Biohaven Presents NURTEC™ (rimegepant) Clinical and Pharmacoeconomic Data at the American Headache Society (AHS) Virtual Annual Scientific Meeting
Jun 10 Biohaven Appoints Bob Hugin to its Board of Directors
Jun 9 Cramer Weighs In On Zynga, Lumentum And More
Jun 9 The Daily Biotech Pulse: Soleno Flunks Late-Stage Study, Sanofi Strikes Breast Cancer Partnership, NanoViricides Shortlists Coronavirus Treatment Candidates
Jun 6 Is Biohaven Pharmaceutical Holding Company Ltd. (BHVN) A Good Stock To Buy?
Jun 5 The Daily Biotech Pulse: Adamas Rallies On FDA Acceptance, Oxford Immunotech Reportedly Gets $400M Bid
Jun 3 The Daily Biotech Pulse: Regulatory Delay For Novartis' Multiple Sclerosis Drug, FSD Gets Nod For COVID-19 Study
Jun 1 Kleo Pharmaceuticals to Present Corporate Overview and Pipeline Update at Jefferies Virtual Healthcare Conference
May 28 3 Reasons Why Biohaven Pharmaceuticals' Stock Is Taking Off
May 21 Kleo Pharmaceuticals and Celularity Enter into Research Collaboration to Rapidly Develop Allogeneic NK Cell Combination Therapies for COVID-19 and Multiple Myeloma
May 18 Biohaven Showcases Clinical and Pharmacoeconomic Data for NURTEC™ ODT (rimegepant) with 25 Presentations on the 2020 American Academy of Neurology (AAN) Science Highlights Virtual Platform
May 16 Biohaven Pharmaceutical Offers Good Value With Nurtec ODT Now On The Market
May 15 Kleo Pharmaceuticals to Present Preclinical Data Highlighting the Synergistic Potential of Kleo Asset KP1237 and Autologous NK Cells in the Treatment of Multiple Myeloma at the 2020 American Society of Clinical Oncology Virtual Meeting
May 7 Biohaven Pharmaceuticals EPS beats by $0.07, beats on revenue
May 7 Biohaven Pharmaceuticals Reports First Quarter 2020 Financial Results and Recent Business Developments
May 4 Why Biohaven (BHVN) Might Surprise This Earnings Season
Apr 27 Biohaven up 5% on rimegepant distribution deal in Middle East

Back to the Main BHVN Page...